Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$456.2MCash on Hand
56.7mo Cash Runway
Follow KRSA by emailGet an email when KRSA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about KRSA, unsubscribe in one click. Privacy
📣 What KRSA Says Is Next
mid-2027 · “Advanced KRSA-028 toward the clinic, with Phase 1 healthy volunteer data expected in mid-2027 and interim proof-of-concept data in patients with Alzheimer’s disease anticipated by year-end 2027 or the first quarter of 2028.”
Company press release, Nov 5, 2026 · SEC filing
mid-2027 · “The Company is advancing KRSA-028 toward the clinic, with Phase 1 healthy volunteer data expected in mid-2027 and interim proof-of-concept data evaluating amyloid plaque clearance in Alzheimer’s disease patients anticipated by the end of 2027 or the first quarter of 2028.”
Company press release, Sep 11, 2026 · SEC filing
mid-2027 · “These include the advancement of KRSA-028 through Phase 1 healthy volunteer data expected in mid-2027 and interim proof of concept data measuring amyloid plaque clearance in Alzheimer’s patients expected by the end of 2027.”
Company press release, Apr 1, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 5, 2026 ·
Earnings Reported Q3 2026 net loss of $46.4 million and R&D expenses of $42.1 million, with cash of $456.2 million funding operations into 2029. Completed merger with Cyclerion and a $380 million private placement; KRSA-028 Phase 1 data expected mid-2027. Form 8-K · SEC filing · Press release
Nov 5, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 15, 2026 ·
Shareholder vote Shareholders will vote Nov 13, 2026 on resubmitting the redomestication from Massachusetts to the Cayman Islands, after the August 26 vote fell short of the two-thirds threshold. Board recommends FOR all three proposals. Form DEF 14A · SEC filing
Sep 11, 2026 ·
Deal Completed merger with Cyclerion Therapeutics and a $380 million private placement, with combined cash of about $475 million expected to fund operations into 2029. Shares begin trading on Nasdaq as KRSA on September 9, 2026, after a 1-for-7 reverse split. Form 8-K · SEC filing · Press release
Aug 27, 2026 ·
Shareholder vote Cyclerion shareholders approved the Nasdaq stock issuance for the Korsana merger, a 700,000,000 authorized share increase, and a reverse split of 1-for-2 to 1-for-10. The redomestication to the Cayman Islands was not approved. Six directors were elected. Form 8-K · SEC filing
Aug 25, 2026 ·
Deal Cyclerion Therapeutics set September 4, 2026 as the record date for distributing contingent value rights to holders of its common and Series A Preferred Stock, tied to its planned merger with Korsana Biosciences. Form 8-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
KRSA holds $456.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $24.1M/quarter from operations,
an estimated runway of 56.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:10 · Low
Cash runway 57 months
ATM program on file since May 2025 +15
Shelf registration (S-3, Feb 2025) +10
Company says cash lasts into 2029 -15We expect that our existing cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditures into 2029.10-Q, Nov 2026
Share count 45,541,358 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full KRSA picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KRSA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.